Envestnet Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Envestnet Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,500	Closed	-$9.55K	–	3975
2023 Q1	$9.55K	Hold	10,500	–	–	﹤0.01%	3950
2022 Q4	$8.93K	Hold	10,500	–	–	﹤0.01%	3940
2022 Q3	$9K	Hold	10,500	–	–	﹤0.01%	3883
2022 Q2	$10K	Hold	10,500	–	–	﹤0.01%	3898
2022 Q1	$17K	Hold	10,500	–	–	﹤0.01%	3906
2021 Q4	$25K	Hold	10,500	–	–	﹤0.01%	3842
2021 Q3	$51K	Hold	10,500	–	–	﹤0.01%	3635
2021 Q2	$28K	Hold	10,500	–	–	﹤0.01%	3618
2021 Q1	$32K	Buy	+10,500	New	+$37.9K	﹤0.01%	3467

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Envestnet Asset Management's CRVS Position: Q2 2023 in Review

Envestnet Asset Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2023, closing a stake of 10,500 shares — an estimated $9.55K sold.

Envestnet Asset Management first reported a position in CRVS in Q1 2021 and held it in 9 quarters. The position peaked at $51K in Q3 2021. 52 funds tracked by Wall St. Rank hold CRVS as of Q2 2023.

Envestnet Asset Management reported no remaining Corvus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Envestnet Asset Management sold 10,500 Corvus Pharmaceuticals shares in Q2 2023, an estimated $9.55K.
Envestnet Asset Management first reported a position in Corvus Pharmaceuticals in Q1 2021 and held it in 9 quarters.
Envestnet Asset Management's Corvus Pharmaceuticals position peaked at $51K in Q3 2021.
52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2023.

Based on Envestnet Asset Management's 13F filing for Q2 2023, filed 4 Aug 2023.